Rosemary has been linked to better memory, lower anxiety and even protection from Alzheimer's
Rosemary (Rosmarinus officinalis), the aromatic herb native to the Mediterranean, has long been treasured in kitchens around the world. But beyond its culinary charm, rosemary is also gaining recognition for its impressive health benefits, especially when it comes to brain health, inflammation and immune function.
Research suggests rosemary may even hold promise in the fight against Alzheimer's disease, the leading cause of dementia worldwide.
Historically, rosemary has been linked to memory and mental clarity. In ancient Greece and Rome, students and scholars used rosemary in the hope of sharpening concentration and recall.
Modern science is finding there may have been something in this: in one study, people who inhaled rosemary's scent performed better on memory tasks compared to those in an unscented environment.
So how does rosemary work on the brain? There are several mechanisms at play. For starters, rosemary stimulates blood circulation, including to the brain, helping deliver more oxygen and nutrients, which may improve mental clarity. It also has calming properties; some studies suggest its aroma can reduce anxiety and improve sleep. Lower stress can mean better focus and memory retention.
Get your news from actual experts, straight to your inbox. Sign up to our daily newsletter to receive all The Conversation UK's latest coverage of news and research, from politics and business to the arts and sciences.
Rosemary contains compounds that interact with the brain's neurotransmitters. One such compound, 1,8-cineole, helps prevent the breakdown of acetylcholine, a brain chemical essential for learning and memory. By preserving acetylcholine, rosemary may help support cognitive performance, especially as we age.
Another bonus? Rosemary is packed with antioxidants, which help protect brain cells from damage caused by oxidative stress – a major factor in cognitive decline.
Rosemary is rich in phytochemicals, plant compounds with health-enhancing effects. One of the most powerful is carnosic acid, an antioxidant and anti-inflammatory agent that helps shield brain cells from harm, particularly from the kinds of damage linked to Alzheimer's disease.
Read more:
In 2025, researchers developed a stable version of carnosic acid called diAcCA. In promising pre-clinical studies, this compound improved memory, boosted the number of synapses (the connections between brain cells), and reduced harmful Alzheimer's related proteins like amyloid-beta and tau.
What's especially exciting is that diAcCA only activates in inflamed brain regions, which could minimise side effects. So far, studies in mice show no signs of toxicity and significant cognitive improvements – raising hopes that human trials could be next.
Researchers also believe diAcCA could help treat other inflammatory conditions, such as type 2 diabetes, cardiovascular disease and Parkinson's disease.
Rosemary's benefits could extend well beyond the brain. It's been used traditionally to ease digestion, relieve bloating and reduce inflammation.
Compounds like rosmarinic acid and ursolic acid are known for their anti-inflammatory effects throughout the body. Rosemary may even benefit the skin – a review suggests it can help soothe acne and eczema, while carnosic acid may offer anti-ageing benefits by protecting skin from sun damage.
Rosemary oil also has antimicrobial properties, showing promise in food preservation and potential pharmaceutical applications by inhibiting the growth of bacteria and fungi.
For most people, rosemary is safe when used in food, teas or aromatherapy. But concentrated doses or extracts can pose risks. Consuming large amounts may cause vomiting or, in rare cases, seizures – particularly in people with epilepsy.
There's also a theoretical risk of rosemary stimulating uterine contractions, so pregnant people should avoid high doses. Because rosemary can interact with some medications – such as blood thinners – it's best to check with a healthcare provider before taking large amounts in supplement form.
Rosemary is more than just a kitchen staple. It's a natural remedy with ancient roots and modern scientific backing. As research continues, particularly into breakthrough compounds like diAcCA, rosemary could play an exciting role in future treatments for Alzheimer's and other chronic conditions.
In the meantime, adding a little rosemary to your life – whether in a meal, a cup of tea, or a breath of its fragrant oil – could be a small step with big health benefits.
This article is republished from The Conversation under a Creative Commons license. Read the original article.
Dipa Kamdar does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory
We came across a bullish thesis on Alpha Cognition Inc. Common Stock (ACOG) by anygal on r/investing on Reddit. In this article, we will summarize the bulls' thesis on ACOG. Alpha Cognition Inc. Common Stock (ACOG)'s share was trading at $9.33 as of 30th May. ACOG's forward P/E was 26.88 according to Yahoo Finance. A chemist in a laboratory analyzing data from the various therapeutic tests conducted. Alpha Cognition Inc. (NASDAQ: ACOG) represents a potentially overlooked opportunity in the Alzheimer's treatment space, having recently launched its oral drug, Zunveyl, at the end of March. With a current market cap of $150 million and $45 million in cash, the company is targeting the underserved segment of the Alzheimer's population—specifically, the 50% of patients in long-term care (LTC) not taking any current medications due to severe side effects. Unlike other galantamine-based drugs, Zunveyl significantly slows disease progression and improves short-term memory with a markedly better safety profile—only one serious side-effect case was reported in its Phase 3 trials, versus a 50% rate seen in traditional options. The drug's Medicare coverage further eases affordability, lowering monthly out-of-pocket costs to $30–$190. Initial demand appears promising, with nearly 500 patients starting treatment in the first two weeks of launch. Even a modest 1% market penetration into the LTC segment could yield $135 million in annual revenue, with $67.5 million in net income assuming 50% margins. A 5% penetration would put net income at $675 million, dwarfing the current valuation. Alpha Cognition has also secured a distribution deal with a major Chinese pharmaceutical firm, creating a royalty-based revenue stream in Asia. While the upside is substantial, key risks remain—most notably, the emergence of unforeseen serious side effects post-launch, which could lead to FDA scrutiny or suspension of sales. Still, the market's underreaction and the company's positioning as a safer, effective alternative in a high-need space make ACOG a high-upside, high-conviction bet for risk-tolerant investors. Previously, we have covered ACOG in March 2025 wherein we summarized a by BullishDoctor on Twitter. The user highlighted that Alpha Cognition Inc.'s drug ZUNVEYL addressed the major side effects of existing Alzheimer's treatments, making it highly tolerable and poised for adoption in long-term care facilities, a $2 billion market. The company was pre-revenue but launched in March 2025 with strong physician support, a nearly complete sales force, and promising catalysts like a Phase 4 study and sublingual formulation, projecting breakeven within three years. Since our last coverage, the stock is up 61% as of 30th May. Alpha Cognition Inc. Common Stock (ACOG) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 8 hedge fund portfolios held ACOG at the end of the first quarter which was 10 in the previous quarter. While we acknowledge the potential of ACOG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Post
2 hours ago
- New York Post
IVF parents are spending thousands to predict their babies' chances of having Alzheimer's, cancer and heart disease
Maybe she's born with it, maybe it's … genetic optimization? Prospective parents using in vitro fertilization (IVF) will soon be able to select embryos based on their potential risk for diseases — including illnesses that develop later in life — thanks to a groundbreaking $5,999 service announced this week by a US biotech company. 'Before there's a heartbeat, there's DNA,' Kian Sadeghi, founder and chief executive of Nucleus Genomics, said in a statement. 'One file containing DNA and genetic markers can tell you more about your baby's future than any other test a doctor could possibly run at this stage.' 4 Supporters say screening could prevent chronic illness, but critics warn it may fuel stigma and inequality. New Africa – What is IVF? The popular fertility treatment involves removing eggs from a woman's ovaries and fertilizing them with sperm in a lab. The resulting embryo — which could be frozen or fresh — is placed into the uterus, where it hopefully implants in the uterine wall and sparks a pregnancy. Before implantation, many IVF clinics already screen embryos for genetic abnormalities — such as extra chromosomes or gene mutations — that can lead to failed implantations, miscarriages, birth defects or inherited disorders. But the first-of-its-kind service from Nucleus Genomics takes things a step further. Build-a-baby The company just launched Nucleus Embryo, a new software platform that lets potential parents dig deep into the full genetic blueprint of their embryos before choosing which one to implant. 4 The number of Americans using IVF has skyrocketed over the last decade. – The tool lets IVF patients compare the DNA of up to 20 embryos, screening them for more than 900 conditions — including Alzheimer's, Type 2 diabetes, heart disease and several forms of cancer. It doesn't stop there. The program also flags potential mental health conditions like depression and schizophrenia and even ranks cognitive traits like IQ. Parents can also get a look at cosmetic and physical features, from height, baldness and BMI to eye and hair color. The company isn't promising perfection. Instead, the software generates a so-called polygenic risk score that will give parents the probability of how likely it is an embryo might develop certain traits or diseases. 4 Many IVF clinics already screen for certain genetic risk factors, like an abnormal number of chromosomes. Charlize Davids/ – Ultimately, it's up to the parents to decide which qualities matter most to them. For those looking to decode the results, genetic counseling sessions are available. 'Lifespan has dramatically increased in the last 150 years,' Sadeghi told the Wall Street Journal. 'DNA testing to predict and reduce chronic disease can make it happen again.' A new era of reproductive tech The practice, known as polygenic embryo screening, is already highly controversial in the medical world, according to a report published by Harvard Law School's Petrie-Flom Center. Critics warn that allowing parents to screen embryos for risks like depression or diabetes could deepen stigma and discrimination against people living with those conditions. Meanwhile, disability advocates argue it promotes the harmful idea that disability is something to be fixed, not a natural part of human diversity. And when it comes to choosing embryos for traits like intelligence or athleticism, critics say we're sliding into designer baby territory — a modern form of eugenics that favors the rich, reinforcing social and healthcare inequalities. 4 Few Americans approve of using the technology to predict traits unrelated to disease. Gemyful – Still, the public appears open to some aspects of the tech. A 2023 survey found that 77% of Americans support using it to screen embryos for the likelihood of developing certain physical conditions, while 72% back screening for mental health risks. Proponents argue it's no different from vaccination — a preventive tool, not a judgment on those with the condition. But when it comes to non-medical traits, support drops fast: only 36% back screening embryos for behavioral traits and just 30% for physical features like height or eye color.
Yahoo
3 hours ago
- Yahoo
Blood test for Alzheimer's could soon be available on the NHS
A new blood test for Alzheimer's disease has been found to accurately detect early symptoms of the illness, according to new research. Experts from the Mayo Clinic in the US examined two proteins in blood plasma – amyloid beta 42/40 and p-tau217 – which are associated with amyloid plaque build-up, a hallmark of Alzheimer's disease, to provide further evidence that blood tests can accurately diagnose dementia. The study, which was carried out on more than 500 people in an outpatient memory clinic, found the blood test was highly accurate, with 95 per cent sensitivity. That means it was 95 per cent accurate in picking up people with memory problems, with very few cases missed. It was also 82 per cent for specificity, meaning it was also highly accurate in ruling out people without dementia. The blood test has already been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the Alzheimer's and Dementia journal, said the test was as good as more invasive tests currently in use. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Dr Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who show no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. 'While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline – though more research in diverse groups of individuals and in community-based setting is still needed. 'Currently diagnosis options in the UK are often slow, expensive and can be invasive, meaning thousands miss out on the benefits one can bring. 'It's great to see blood tests like this approved for clinical use in the US – we hope to see the same in the NHS, which is why we're part of the Blood Biomarker Challenge.' The Blood Biomarker Challenge is a multi-million-pound research programme supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research. Its goal is to bring blood tests for dementia diagnosis to the NHS by 2029. Dr Julia Dudley, head of research at Alzheimer's Research UK, said: 'We urgently need to improve how we diagnose dementia and it's great to see international research working towards this goal. 'Blood tests in this study look at p-tau217 and amyloid beta 42/40, and showed the tests offered high accuracy in confirming Alzheimer's disease. 'This study adds to the growing evidence that blood tests can detect the diseases that cause dementia in people with early memory and thinking problems. 'An important point to consider is that people taking part in research don't always reflect the full diversity of those affected by dementia, who might have additional conditions or other characteristics. 'That is why work is needed to understand whether these blood tests work in a real-world setting.'
